

Own development of the ENT* area

REIG JOFRE CONTINUES TO STRENGTHEN ITS LEADERSHIP IN ENT WITH THE LAUNCH OF **OTOSPRAY® 3E** EAR HYGIENE

- Reig Jofre expands the otolaryngology range, with the launch of an innovative new product, **Otospray® 3E**.
- Due to its novel form of action, **Otospray® 3E** is indicated in the daily hygiene of the ear canal and in the elimination of excess of cerumen, thus preventing the formation of earwax.

Barcelona (Spain), September 13, 2017. The pharmaceutical company Reig Jofre reinforces its area of therapeutic specialization products in the Respiratory/ENT range with the launch of **Otospray® 3E** developed by its research department, which, due to its effectiveness and form of action, presents a novelty in the market of the hygiene and health of the ear.



Due to its formulation, **Otospray® 3E** acts on the dirt and excess of cerumen present in the ear canal by **Emulsifying**, **Encapsulating** and **Eliminating** them in a single action, thus contributing to the prevention of earwax. In a single spray Otospray® **3E** all in one.

Otospray® 3E is available in two forms: **Otospray® 3E** 100 ml, suitable for adults and children over 6 years of age, and **Otospray® 3E** Junior 50 ml for children from 2 years of age and adults requiring a smoother spray.

*ENT: Ear, nose and throat



Otospray® 3E for the daily hygiene of the whole family, expands the range for the overall health of the ear, which is combined with **Otocerum®**, otic drops in solution, the market leader in Spain for the dissolution and painless removal of the earwax. Hygiene and prevention of excess of cerumen: **Otospray® 3E**. Dissolution of the earwax: **Otocerum®**.

In addition, Reig Jofre's ENT range also has the exclusive license for Spain of Sterimar®, isotonic sea water spray for the daily nasal hygiene of the whole family.

Reig Jofre started the marketing of Otospray® in Spain, where the company has a commercial network of over one hundred sales representatives, specialized in practitioner, hospital and pharmacy channels, while it is also planning to expand its commercialization in Europe.

Reig Jofre closed 2016 with a turnover of 161 million euros, of which 60% outside Spain, through its own sales networks in Europe and commercial relations with more than 130 partners (distributors and licensees) in 64 countries in the five continents. The Respiratory/ENT range contributed 8.4 million euros in 2016 and grew 25% over the previous year.

Get timely updates of Reig Jofre news by registering in the company's **subscription centre** on the corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in Barcelona in 1929, Reig Jofre is a multinational pharmaceutical company with activity structured around two major axes: the main one, own-product manufacture and marketing (RJF Pharma, 80% of total sales) and a complementary one, development and manufacture for third parties (RJF CDMO, 20% of total sales). In its main activity, the company focuses on developing specialised technological products (antibiotics and solutions for injection); specialised therapeutic products for the dermatology, gynaecology and respiratory fields; and dietary supplements and consumer healthcare. The company focuses its R+D activity on developing new indications and/or pharmaceutical forms using known active substances, generic medicines with a particular focus on beta-lactam antibiotics and solutions for injection, topical dermatological products, OTCs and dietary supplements, and in addition develops new innovative molecules in partnership with start-ups and research centres.

Reig Jofre has over 900 employees, 4 development centres and 4 production centres in Europe, direct sales in 7 countries and over 130 business partners in 64 countries across the world. The company closed 2016 with a turnover of 161 million euros.

Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Share capital: 64,153,178 shares.



For further information:

Investors and analysts

Gloria Folch

Tel. (+34) 93 480 67 10 – ext. 1241

gloria.folch@reigjofre.com

Media

Inma Santa-Pau

Tel. (+34) 93 480 67 10 – ext. 1242

inma.santapau@reigjofre.com